Buy this article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.



July 2012, Volume 42 Number 7 , p 9 - 9



The FDA has issued new warnings about the risks associated with antihypertensive agents containing aliskiren (a renin inhibitor) when given with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). These combinations are contraindicated in patients with diabetes because of the risk of renal impairment, hypotension, and hyperkalemia. In addition, the labeling contains a warning to avoid combining aliskiren with ACEIs or ARBs in patients with renal impairment (glomerular filtration rate < 60 mL/min.).Tell patients taking aliskiren that they shouldn't stop taking the drug without talking to their healthcare provider. Warn them that suddenly stopping the drug may cause hypertension.Source: FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekuturna). .The FDA recently approved levofloxacin to treat patients with plague, a rare but potentially

To continue reading, buy this article for just $3.95.

Have a coupon or promotional code? Enter it here: